Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

Krisztián Szigeti; Nikolett Hegedus; Kitti Rácz; Ildikó Horváth; Dániel S. Veres; Dávid Szöllosi; Ildikó Futó; Károly Módos; Tamás Bozó; Kinga Karlinger; Noémi Kovács; Zoltán Varga; Magor Babos; Ferenc Budán; Parasuraman Padmanabhan; Balázs Gulyás; Domokos Máthé

doi:10.1155/2018/2023604

Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

Krisztián Szigeti, Nikolett Hegedus, Kitti Rácz, Ildikó Horváth, Dániel S. Veres, Dávid Szöllosi, Ildikó Futó, Károly Módos, Tamás Bozó, Kinga Karlinger, Noémi Kovács, Zoltán Varga, Magor Babos, Ferenc Budán, Parasuraman Padmanabhan, Balázs Gulyás, Domokos Máthé

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with ²⁰¹ Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with ²⁰¹ Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm ³ ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

Original language	English (US)
Article number	2023604
Journal	Contrast Media and Molecular Imaging
Volume	2018
DOIs	https://doi.org/10.1155/2018/2023604
State	Published - Apr 26 2018
Externally published	Yes

Bibliographical note

Funding Information:
The authors acknowledge the helpful discussions of Miklós Kellermayer (Department of Biophysics and Radiation Biology, Semmelweis University). Dr. Levente Mészáros (King’s College, London) is gratefully acknowledged for valuable contributions in editing and proofing the manuscript. The high value technical support in SPECT/MRI image acquisitions from Mediso (Gábor Németh, Sándor Hóbor) is gratefully acknowledged. The research leading to these results has received funding from the European Union’s Seventh Frame-work Programme (FP7/2007-2013) under Grant Agreements HEALTH-F2-2011-278850 (INMiND), FP7 HEALTH-305311 (INSERT), and TÁMOP-4.2.1./B-09/1/KMR-2010-0001. This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program). Krisztián Szigeti was supported by the Janos Bolyai Research Fellowship Program of the Hungarian Academy of Science. Parasuraman Padmanabhan and Balázs Gulyás acknowledge the support from the Lee Kong Chian School of Medicine, Nanyang Technological University Start-Up Grant.

Publisher Copyright:
© 2018 Krisztián Szigeti et al.

Access

10.1155/2018/2023604

Cite this

Szigeti, K., Hegedus, N., Rácz, K., Horváth, I., Veres, D. S., Szöllosi, D., Futó, I., Módos, K., Bozó, T., Karlinger, K., Kovács, N., Varga, Z., Babos, M., Budán, F., Padmanabhan, P., Gulyás, B., & Máthé, D. (2018). Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent. Contrast Media and Molecular Imaging, 2018, [2023604]. https://doi.org/10.1155/2018/2023604

Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent. / Szigeti, Krisztián; Hegedus, Nikolett; Rácz, Kitti; Horváth, Ildikó; Veres, Dániel S.; Szöllosi, Dávid; Futó, Ildikó; Módos, Károly; Bozó, Tamás; Karlinger, Kinga; Kovács, Noémi; Varga, Zoltán; Babos, Magor; Budán, Ferenc; Padmanabhan, Parasuraman; Gulyás, Balázs; Máthé, Domokos.

In: Contrast Media and Molecular Imaging, Vol. 2018, 2023604, 26.04.2018.

Research output: Contribution to journal › Article › peer-review

Szigeti, K, Hegedus, N, Rácz, K, Horváth, I, Veres, DS, Szöllosi, D, Futó, I, Módos, K, Bozó, T, Karlinger, K, Kovács, N, Varga, Z, Babos, M, Budán, F, Padmanabhan, P, Gulyás, B & Máthé, D 2018, 'Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent', Contrast Media and Molecular Imaging, vol. 2018, 2023604. https://doi.org/10.1155/2018/2023604

Szigeti, Krisztián ; Hegedus, Nikolett ; Rácz, Kitti ; Horváth, Ildikó ; Veres, Dániel S. ; Szöllosi, Dávid ; Futó, Ildikó ; Módos, Károly ; Bozó, Tamás ; Karlinger, Kinga ; Kovács, Noémi ; Varga, Zoltán ; Babos, Magor ; Budán, Ferenc ; Padmanabhan, Parasuraman ; Gulyás, Balázs ; Máthé, Domokos. / Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent. In: Contrast Media and Molecular Imaging. 2018 ; Vol. 2018.

@article{302543ff6edb4c37a1021f9265c213be,

title = "Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent",

abstract = " Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201 Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201 Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm 3 ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications. ",

author = "Kriszti{\'a}n Szigeti and Nikolett Hegedus and Kitti R{\'a}cz and Ildik{\'o} Horv{\'a}th and Veres, {D{\'a}niel S.} and D{\'a}vid Sz{\"o}llosi and Ildik{\'o} Fut{\'o} and K{\'a}roly M{\'o}dos and Tam{\'a}s Boz{\'o} and Kinga Karlinger and No{\'e}mi Kov{\'a}cs and Zolt{\'a}n Varga and Magor Babos and Ferenc Bud{\'a}n and Parasuraman Padmanabhan and Bal{\'a}zs Guly{\'a}s and Domokos M{\'a}th{\'e}",

note = "Funding Information: The authors acknowledge the helpful discussions of Mikl{\'o}s Kellermayer (Department of Biophysics and Radiation Biology, Semmelweis University). Dr. Levente M{\'e}sz{\'a}ros (King{\textquoteright}s College, London) is gratefully acknowledged for valuable contributions in editing and proofing the manuscript. The high value technical support in SPECT/MRI image acquisitions from Mediso (G{\'a}bor N{\'e}meth, S{\'a}ndor H{\'o}bor) is gratefully acknowledged. The research leading to these results has received funding from the European Union{\textquoteright}s Seventh Frame-work Programme (FP7/2007-2013) under Grant Agreements HEALTH-F2-2011-278850 (INMiND), FP7 HEALTH-305311 (INSERT), and T{\'A}MOP-4.2.1./B-09/1/KMR-2010-0001. This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program). Kriszti{\'a}n Szigeti was supported by the Janos Bolyai Research Fellowship Program of the Hungarian Academy of Science. Parasuraman Padmanabhan and Bal{\'a}zs Guly{\'a}s acknowledge the support from the Lee Kong Chian School of Medicine, Nanyang Technological University Start-Up Grant. Publisher Copyright: {\textcopyright} 2018 Kriszti{\'a}n Szigeti et al.",

year = "2018",

month = apr,

day = "26",

doi = "10.1155/2018/2023604",

language = "English (US)",

volume = "2018",

journal = "Contrast Media and Molecular Imaging",

issn = "1555-4309",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

AU - Szigeti, Krisztián

AU - Hegedus, Nikolett

AU - Rácz, Kitti

AU - Horváth, Ildikó

AU - Veres, Dániel S.

AU - Szöllosi, Dávid

AU - Futó, Ildikó

AU - Módos, Károly

AU - Bozó, Tamás

AU - Karlinger, Kinga

AU - Kovács, Noémi

AU - Varga, Zoltán

AU - Babos, Magor

AU - Budán, Ferenc

AU - Padmanabhan, Parasuraman

AU - Gulyás, Balázs

AU - Máthé, Domokos

N1 - Funding Information: The authors acknowledge the helpful discussions of Miklós Kellermayer (Department of Biophysics and Radiation Biology, Semmelweis University). Dr. Levente Mészáros (King’s College, London) is gratefully acknowledged for valuable contributions in editing and proofing the manuscript. The high value technical support in SPECT/MRI image acquisitions from Mediso (Gábor Németh, Sándor Hóbor) is gratefully acknowledged. The research leading to these results has received funding from the European Union’s Seventh Frame-work Programme (FP7/2007-2013) under Grant Agreements HEALTH-F2-2011-278850 (INMiND), FP7 HEALTH-305311 (INSERT), and TÁMOP-4.2.1./B-09/1/KMR-2010-0001. This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program). Krisztián Szigeti was supported by the Janos Bolyai Research Fellowship Program of the Hungarian Academy of Science. Parasuraman Padmanabhan and Balázs Gulyás acknowledge the support from the Lee Kong Chian School of Medicine, Nanyang Technological University Start-Up Grant. Publisher Copyright: © 2018 Krisztián Szigeti et al.

PY - 2018/4/26

Y1 - 2018/4/26

N2 - Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201 Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201 Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm 3 ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

AB - Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201 Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201 Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm 3 ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

UR - http://www.scopus.com/inward/record.url?scp=85046630255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046630255&partnerID=8YFLogxK

U2 - 10.1155/2018/2023604

DO - 10.1155/2018/2023604

M3 - Article

C2 - 29853803

AN - SCOPUS:85046630255

VL - 2018

JO - Contrast Media and Molecular Imaging

JF - Contrast Media and Molecular Imaging

SN - 1555-4309

M1 - 2023604

ER -

Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

Abstract

Bibliographical note

Access

Other files and links

Fingerprint

Cite this